Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17995535 | 0.82 | ESR1 (0.55) | ESR1LMNACYP2C19CYP3A4CYP2D6 | |
| SCHEMBL17995536 | 0.80 | ESR1 (0.53) | ESR1LMNATSHRESR2KDM4E | |
| SCHEMBL24818431 | 0.78 | ESR1 (0.35) | ESR1CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL14670886 | 0.77 | ESR1 (0.47) | ESR1CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL24818411 | 0.76 | ESR1 (0.36) | ESR1CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL16608746 | 0.75 | LMNA (0.50) | ESR1LMNATSHRGAAALOX15 | |
| SCHEMBL2772290 | 0.73 | LMNA (0.52) | ESR1LMNACYP2C19CYP2D6ESR2 | |
| SCHEMBL22725623 | 0.72 | EGFR (0.43) | KDM4EL3MBTL1 | |
| SCHEMBL7712163 | 0.72 | DNM2 (0.47) | ESR1LMNACYP2C19GAAPOLB | |
| SCHEMBL17995534 | 0.71 | CYP3A4 (0.46) | ESR1CYP2C19CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868705-B2 | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868705-B2 | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | DUKE UNIVERSITY | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | AR, FSHR, ESRRB | ESR1 81/4885LMNA 4775/4885CYP2C19 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.